Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$18.83 USD
-0.88 (-4.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $18.82 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BEAM 18.83 -0.88(-4.46%)
Will BEAM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Innovation ETF (ARKK) Hits New 52-Week High
3 Promising Genomics Stocks to Keep an Eye On in 2025
Other News for BEAM
Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off
Cathie Wood's ARK Investment buys 659K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 29K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 55K shares of Beam Therapeutics today
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies